Quick Answer
Indivior Pharmaceuticals, Inc. reported Total Revenue of $1.24 billion for the year ending 2025.
- Indivior Pharmaceuticals, Inc. showed an increase of +4.3% in Total Revenue from 2024 to 2025.
- This data is from Indivior Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2022 to 2025 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2024: $284.00 million | Q2 2024: $299.00 million | Q3 2024: $307.00 million | Q1 2025: $266.00 million | Q2 2025: $302.00 million | Q3 2025: $314.00 million.
- Over the full 4 years of available data (2022 to 2025), Indivior Pharmaceuticals, Inc.'s Total Revenue has grown by 37.5%.
- Historical annual values: Fiscal year 2025: $1.24 billion | Fiscal year 2024: $1.19 billion | Fiscal year 2023: $1.09 billion | Fiscal year 2022: $901.00 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: